David Ricks

David Ricks

business United States

David Ricks is the Chief Executive Officer of Eli Lilly and Company, a leading pharmaceutical company known for its innovations in diabetes and weight loss medications, including Zepbound and Mounjaro. Under his leadership, the company announced a significant $27 billion investment to expand its manufacturing capabilities in the United States, aiming to bolster domestic production in response to potential tariffs and supply chain vulnerabilities exposed during the COVID-19 pandemic. Ricks has emphasized the importance of reshoring production and increasing manufacturing capacity to meet the growing demand for Eli Lilly's products.

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
8,014
Power
648$
Sentiment
8.00
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
Switzerland 1 8.00 0.09% +0% 8,654,622 8,014 $700,000 648$
Totals 1 8,654,622 8,014 $700,000 648$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Luxembourg Luxembourg: David Ricks is the CEO of Eli Lilly who was speaking about a weight loss drug deal when the incident occurred. 5

Luxemburger Wort: Mann kollabiert bei Trump-Pressekonferenz im Oval Office

United Kingdom United Kingdom: David Ricks, Eli Lilly's chief executive, said in a statement that Lilly is in a unique position to work with the US government to rebalance the global system. 8

BBC: Trump unveils deals to lower US weight-loss drug prices

Ireland Ireland: David Ricks is Eli Lilly’s chief executive who commented on the potential of the new weight-loss pill. 8

The Irish Times – major Irish daily, est. 1859: Lilly’s weight loss pill is a ‘landmark moment’ in the obesity fight – The Irish Times

Ireland Ireland: David Ricks, Eli Lilly’s chief executive, stated that orforglipron may provide a new option for weight management. 8

The Irish Times – major Irish daily, est. 1859: New daily weight-loss pill shows success at clinical trial – The Irish Times